Targeting inflammation in heart failure with histone deacetylase inhibitors

Area of Science:

• Cardiovascular Medicine
• Molecular Biology
• Immunology

Background:

• Cardiovascular insults like myocardial infarction and hypertension induce pathological cardiac remodeling, involving myocyte hypertrophy, death, and fibrosis, leading to heart failure.
• Inflammation plays a crucial role in pathological cardiac remodeling and heart failure progression.
• Therapeutic strategies targeting inflammatory pathways show potential for managing heart failure.

Purpose of the Study:

• To review the roles of histone deacetylases (HDACs) in the heart.
• To explore the potential of HDAC inhibitors as therapeutic agents for heart failure.
• To highlight the immunomodulatory effects of HDAC inhibitors in the context of heart failure.

Main Methods:

• Review of existing literature on HDACs in cardiac remodeling and inflammation.
• Analysis of preclinical data from animal models using HDAC inhibitors.
• Discussion of the anti-inflammatory actions of HDAC inhibitors.

Main Results:

• Small molecule HDAC inhibitors have demonstrated efficacy in blocking adverse cardiac remodeling in animal models.
• HDAC inhibitors possess potent anti-inflammatory properties beyond their effects on myocardial cells.
• These findings suggest HDAC inhibitors could counteract both the cellular and inflammatory aspects of heart failure.

Conclusions:

• HDACs play significant roles in the heart, influencing cardiac remodeling and inflammation.
• HDAC inhibitors represent a promising therapeutic class for heart failure, addressing both structural changes and inflammatory processes.
• The immunomodulatory actions of HDAC inhibitors suggest their potential as broad-based treatments for human heart failure.